{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:53:34Z","timestamp":1776228814435,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022910","name":"Cross Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022910","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.leukres.2026.108206","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:39:41Z","timestamp":1773941981000},"page":"108206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of measurable residual disease on outcomes using a modified DFCI protocol for adults with BCR-ABL negative acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9095-8789","authenticated-orcid":false,"given":"Joseph","family":"Brandwein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Szkotak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.leukres.2026.108206_bib1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review","volume":"4","author":"Siegel","year":"2018","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2026.108206_bib2","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1016\/S2352-3026(24)00285-0","article-title":"Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia","volume":"11","author":"Aldoss","year":"2024","journal-title":"Lancet Haematol."},{"issue":"14","key":"10.1016\/j.leukres.2026.108206_bib3","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108206_bib4","article-title":"Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia \u2013 GRAALL-2014 trial","author":"Boissel","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108206_bib5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18\u201350 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108206_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","article-title":"Treatment of adults with BCR-ABL negative acute lymphoblastic leukemia (ALL) with a modified pediatric regimen","volume":"146","author":"Storring","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"23","key":"10.1016\/j.leukres.2026.108206_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood.V126.23.80.80","article-title":"A Multicenter Phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCI ALL consortium trial","volume":"126","author":"DeAngelo","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.leukres.2026.108206_bib8","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2026.108206_bib9","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.leukres.2026.108206_bib10","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2023020794","article-title":"Diagnosis, prognostic factors and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"Gokbuget","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2026.108206_bib11","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/bloodadvances.2021006727","article-title":"Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods","volume":"6","author":"Kotrov\u00e1","year":"2022","journal-title":"Blood Adv."},{"issue":"14","key":"10.1016\/j.leukres.2026.108206_bib12","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108206_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2026.108206_bib14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bjh.12561","article-title":"Treatment of elderly patients with acute lymphoblastic leukemia with a pediatric-based protocol","volume":"163","author":"Poch Martell","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108206_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2024-207450","article-title":"Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk pediatric b-acute lymphoblastic leukemia: results from the randomized children's oncology group study AALL1731","volume":"144","author":"Rau","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2026.108206_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2026.108206_bib17","first-page":"273","article-title":"Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome\u2013negative B-precursor ALL","volume":"42","author":"Stelljes","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108206_bib18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108206_bib19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:01:00Z","timestamp":1776225660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":19,"alternative-id":["S0145212626000500"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108206","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of measurable residual disease on outcomes using a modified DFCI protocol for adults with BCR-ABL negative acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108206"}}